← Back to Search

Contrast Enhanced Ultrasound for Kidney Cancer

Phase 4
Recruiting
Led By Jordan Swennson, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Previously identified renal mass with radiology and clinical features consistent with RCC
Clinical care plan includes partial or total nephrectomy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 6 months
Awards & highlights

Study Summary

This trial will help doctors better understand how to use imaging to grade renal cell carcinoma, which in turn will help them make treatment decisions.

Who is the study for?
This trial is for adults over 18 with a kidney mass suspected to be renal cell carcinoma (RCC), based on imaging and clinical data, who are planned to undergo partial or total removal of the kidney. It's not for those under 18, pregnant women, cases where the mass isn't likely RCC or can't be seen by standard ultrasound, known blood clot in the kidney vein, or if surgery isn't planned.Check my eligibility
What is being tested?
The study aims to see if contrast-enhanced ultrasound using Lumason can predict how aggressive a kidney cancer is by matching its appearance on this special scan with the tumor grade after it's surgically removed. The hypothesis is that different grades of tumors will show unique enhancement patterns and blood flow characteristics.See study design
What are the potential side effects?
Lumason used in contrast-enhanced ultrasounds may cause side effects like allergic reactions including rash, headache, nausea, altered taste sensation; rarely serious heart problems or severe allergic reactions might occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney tumor is identified as renal cell carcinoma.
Select...
My treatment plan includes surgery to remove part or all of my kidney.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and first 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Correlation of contrast enhanced ultrasound features of renal masses with pathologic grade

Trial Design

1Treatment groups
Experimental Treatment
Group I: Renal malignancyExperimental Treatment1 Intervention
Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
980 Previous Clinical Trials
981,761 Total Patients Enrolled
Jordan Swennson, MDPrincipal InvestigatorIndiana University

Media Library

Contrast enhanced ultrasound with Lumason Clinical Trial Eligibility Overview. Trial Name: NCT03821376 — Phase 4
Kidney Cancer Research Study Groups: Renal malignancy
Kidney Cancer Clinical Trial 2023: Contrast enhanced ultrasound with Lumason Highlights & Side Effects. Trial Name: NCT03821376 — Phase 4
Contrast enhanced ultrasound with Lumason 2023 Treatment Timeline for Medical Study. Trial Name: NCT03821376 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks have been associated with Contrast enhanced ultrasound using Lumason?

"A score of 3 reflects the fact that Contrast Enhanced Ultrasound with Lumason has been approved and is in Phase 4. Therefore, it can be assumed to have a high level of safety."

Answered by AI

Is there an ongoing call for participants in this experiment?

"Absolutely, according to clinicaltrials.gov this medical trial is actively searching for volunteers and was first posted on July 16th 2019. The most recent update was recorded as of 12th July 2022, with the aim of finding 40 individuals at a single site."

Answered by AI

Is this an original investigation?

"Utilizing Lumason with contrast enhanced ultrasound has been explored by researchers since 2017, when the first study to examine this intervention was sponsored by Bracco Diagnostics. Following a successful Phase < 1 drug approval in late 2017, 14 distinct medical studies have been launched across 10 urban centres located within 3 nations."

Answered by AI

What is the recruitment size of this experiment?

"Correct. The information hosted on clinicaltrials.gov corroborates that this research trial, which was originally posted to the platform in July of 2019, is actively searching for participants. 40 patients are required from a single location."

Answered by AI

Have there been precedents of Contrast enhanced ultrasound with Lumason in clinical trials?

"Currently, there are 14 active trials for Contrast enhanced ultrasound with Lumason, two of which currently reside in the third phase. Most take place at sites within Philadelphia, Pennsylvania; though overall there are 18 study locations across America."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
Jordan K. Swensson 2019. "Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03821376.
~8 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top